Chemical formula: C₈₈H₁₀₀Cl₂N₁₀O₂₈ Molecular mass: 1,814.609 g/mol PubChem compound: 23724878
Dalbavancin interacts in the following cases:
In patients with chronic renal impairment whose creatinine clearance is <30 ml/min and who are not receiving regularly scheduled haemodialysis, the recommended dose is reduced to either 1,000 mg administered as a single infusion or 750 mg followed one week later by 375 mg.
Caution should be exercised when prescribing dalbavancin to patients with moderate or severe hepatic impairment (Child-Pugh B & C) as no data are available to determine appropriate dosing.
Studies in animals have shown reduced fertility. The potential risk for humans is unknown.
Antibacterial-associated colitis and pseudomembranous colitis have been reported with the use of nearly all antibiotics and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the treatment with dalbavancin. In such circumstance, the discontinuation of dalbavancin and the use of supportive measures together with the administration of specific treatment for Clostridioides (formerly Clostridium) difficile should be considered. These patients must never be treated with medicinal products that suppress the peristalsis.
Dalbavancin should be administered with caution in patients known to be hypersensitive to other glycopeptides since cross-hypersensitivity may occur. If an allergic reaction to dalbavancin occurs, administration should be discontinued and appropriate therapy for the allergic reaction should be instituted.
There are no data from the use of dalbavancin in pregnant women. Studies in animals have shown reproductive toxicity.
Dalbavancin is not recommended during pregnancy, unless the potential expected benefit clearly justifies the potential risk to the foetus.
It is unknown whether dalbavancin is excreted in human milk. However, dalbavancin is excreted in the milk of lactating rats and may be excreted in human breast milk. Dalbavancin is not well absorbed orally; however, an impact on the gastrointestinal flora or mouth flora of a breast-feeding infant cannot be excluded. A decision must be made whether to continue/discontinue breast-feeding or to continue/discontinue therapy with dalbavancin taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Studies in animals have shown reduced fertility. The potential risk for humans is unknown.
Dalbavancin may have a minor influence on the ability to drive and use machines, as dizziness has been reported in a small number of patients.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
